The Covid sales boom is over for Pfizer

Pfizer generated nearly $57 billion in combined sales last year from its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill. That works out to almost 60% of the company’s total revenue for 2022. But the boom appears to be over. Pfizer (PFE) told Wall Street Tuesday that it expects…#comirnaty #paxlovid #pfe #bntx #pfizer #refinitiv #albertbourla #arenapharmaceuticals #rsv
Source: Reuters: Health - Category: Consumer Health News Source Type: news